A good proportion of FLT3 wild-type patients display response to FLT3 inhibitors, suggesting that genomic profiling alone may not provide optimal patient stratification; however, little data is currently available on the role that these combinations play in controlling oncogenic signaling in FLT3 wild-type AML. Here, FLT3 is linked to acute myeloid leukemia.